Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

203811 Bryostatin 1 - CAS 83314-01-6 - Calbiochem

203811
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

Empirical FormulaCAS #
C₄₇H₆₈O₁₇83314-01-6

Products

Catalogue NumberPackaging Qty/Pack
203811-10UG Plastic ampoule 10 μg
Description
OverviewA macrocyclic lactone with antitumor properties. Potently activates protein kinase C and exhibits a high binding affinity (Ki = 1.35 nM). Effectively translocates and down-regulates PKC isozymes α, δ, and ε. Induces a biphasic activation of PKD through a PKC-dependent pathway in intact cells. Also shown to activate Ras in Jurkat T cells and in rat2 cells.
Catalogue Number203811
Brand Family Calbiochem®
SynonymsBryo 1, PKC Activator VII, PKC Activator VI
References
ReferencesClamp, A., and Jayson, G. 2002. Anticancer Drugs 13, 673.
Lorenzo, P.S., et al. 1999. Cancer Res. 59, 6137.
Wang, Q.J., et al. 1999. J. Biol. Chem. 274, 37233.
Wender, P.A., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 6624.
Matthews, S.A., et al. 1997. J. Biol. Chem. 272, 20245.
Szallasi, Z., et al. 1994. Mol. Pharmacol. 46, 840.
Berkow, R.L., and Kratt, A.S. 1985. Biochem. Biophys. Res. Commun. 3, 1109.
Product Information
CAS number83314-01-6
ATP CompetitiveN
FormWhite to colorless solid or film
Hill FormulaC₄₇H₆₈O₁₇
Chemical formulaC₄₇H₆₈O₁₇
ReversibleN
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary TargetProtein kinase C
Primary Target K<sub>i</sub>1.35 nM for protein kinase C
Purity≥98% by HPLC
Physicochemical Information
Cell permeableN
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
RTECSEH9455000
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage -20°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Transport Information
Supplemental Information
Specifications

Documentation

Bryostatin 1 - CAS 83314-01-6 - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

Bryostatin 1 - CAS 83314-01-6 - Calbiochem Certificates of Analysis

TitleLot Number
203811

References

Reference overview
Clamp, A., and Jayson, G. 2002. Anticancer Drugs 13, 673.
Lorenzo, P.S., et al. 1999. Cancer Res. 59, 6137.
Wang, Q.J., et al. 1999. J. Biol. Chem. 274, 37233.
Wender, P.A., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 6624.
Matthews, S.A., et al. 1997. J. Biol. Chem. 272, 20245.
Szallasi, Z., et al. 1994. Mol. Pharmacol. 46, 840.
Berkow, R.L., and Kratt, A.S. 1985. Biochem. Biophys. Res. Commun. 3, 1109.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision17-December-2018 JSW
SynonymsBryo 1, PKC Activator VII, PKC Activator VI
DescriptionA macrocyclic lactone that exhibits anti-tumor properties. Potently activates protein kinase C and exhibits high binding affinity (Ki = 1.35 nM). Effectively translocates protein kinase C (PKC) isozymes α, β, and ε and induces a biphasic, concentration-dependent, down-regulation of PKC δ. Reported to compete with phorbol esters in binding to PKC. Stimulates protein kinase D (PKD) activity in a biphasic, PKC-dependent manner in intact cells. Also activates Ras in Jurkat T cells and in rat2 cells.
FormWhite to colorless solid or film
CAS number83314-01-6
RTECSEH9455000
Chemical formulaC₄₇H₆₈O₁₇
Structure formulaStructure formula
Purity≥98% by HPLC
SolubilityDMSO (25 mg/ml) or Ethanol (25 mg/ml)
Storage -20°C
Protect from light
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
Merck USA index14, 1457
ReferencesClamp, A., and Jayson, G. 2002. Anticancer Drugs 13, 673.
Lorenzo, P.S., et al. 1999. Cancer Res. 59, 6137.
Wang, Q.J., et al. 1999. J. Biol. Chem. 274, 37233.
Wender, P.A., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 6624.
Matthews, S.A., et al. 1997. J. Biol. Chem. 272, 20245.
Szallasi, Z., et al. 1994. Mol. Pharmacol. 46, 840.
Berkow, R.L., and Kratt, A.S. 1985. Biochem. Biophys. Res. Commun. 3, 1109.